IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Bozung, K-H et al U.S. Appln. No. : 10/608,753 Confirmation No. : 7182 U.S. Filing Date : 06/27/2003 Title of Invention : Medicament Compositions Compounds and Betamime Attny. Docket No. : 1/1088-3-C2		Edward J. Webman
Mail Stop Amendment Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450		
March 15, 2007		
TRANSMITTAL LETTER FOR INFOR	MATION DISCL	OSURE STATEMENT
Sir:		
In accordance with the duty of disclosure under the U.S. Patent and Trademark Office of the do- form PTO/SB/08a and which the Examiner may of the above-identified application.	cuments listed her	rein and on the attached
1.97(b). This Statement is being f date of a national application other than a contin §1.53 (d); ii) within three (3) months of the date 37 C.F.R. §1.491 in an international application on the merits; or iv) before the mailing of a first continued examination under 37 C.F.R. §1.114.	nued prosecution a e of entry of the na e; iii) before the m t Office action after	ational stage as set forth in ailing of a first Office action
Notice of allowance under 37 C.F.R. §1.311, or prosecution in the application. This Statement is being for the mailing date of: notice of allowance under 37 C.F.R. §1.311, or prosecution in the application. This Statement is	i) a final action unii) an action that	nder 37 C.F.R. §1.113, ii) a otherwise closes
A statement as specified in 37 C	.F.R. §1.97(e) [see	e below]; or
The fee set forth in 37 C.F.R. §1	.17(p).	

		The Director is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
	ent as s	This Statement is being filed after the period specified in 37 C.F.R. on or before payment of the issue fee. This Statement is accompanied by a pecified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R.
	1.97(e).
	counte	Each item of information contained in the instant information disclosure tent was first cited in any communication from a foreign patent office in a terpart foreign application not more than three (3) months prior to the filing of stant information disclosure statement; or
	foreign makin inform C.F.R.	No item of information contained in the instant information disclosure tent was cited in a communication from a foreign patent office in a counterpart in application, and, to the knowledge of the person signing this certification after g reasonable inquiry, no item of information contained in the instant nation disclosure statement was known to any individual designated in 37 at \$1.56(c) more than three (3) months prior to the filing of the instant nation disclosure statement.
		The fee set forth in 37 C.F.R. §1.17(p).
		The Director is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
counte in sect	rpart ap ion 1.50	(d). Each item of information contained in the accompanying information tement was cited in a communication from a foreign patent office in a oplication, which communication was not received by any individual designated 6(c) more than thirty (30) days prior to the filing of the accompanying isclosure statement.

The Director is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Respectfully submitted,

/wendy petka/

Wendy Petka Attorney for Applicants Reg. No. 53,549

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT 06877

Tel: (203) 791-6614 Fax: (203) 798-4408

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

1/1088-3-C2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/608,753 Filing Date INFORMATION DISCLOSURE 06/27/2003 First Named Inventor Karl-Heinz BOZUNG STATEMENT BY APPLICANT Art Unit 1614 Examiner Name E. WEBMAN (Use as many sheets as necessary)

Sheet

Attorney Docket Number

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-6,908,928	06/21/2005	Bankalaar Balf at al	ga. ac. , .ppca.
				Banholzer, Rolf, et al	
		^{US-} 6,777,423	08/17/2004	Banholzer, Rolf, et al	
		^{US-} 4,814,161	03/21/1989	Jinks, Philip, A., et al	
		^{US-} 5,795,564	08/18/1998	Aberg, Gunnar, et al	
		^{US-} 6,537,524	03/25/2003	Hassan, lan, F., et al	
		^{US-} 2002/0052312	05/02/2002	Reiss, Thomas, et al	
		^{US-} 6,303,103	10/16/2001	Akehurst, Rachel A., et a	
		^{US-} 2003/0066524	04/10/2003	Hochrainer, Dieter, et al	
		^{US-} 2005/0159441	07/21/2005	Hochrainer, Dieter, et al	
		^{US-} 6,481,435	11/19/2002	Hochrainer, Dieter, et al	
		^{US-} 2004/0087793	05/06/2004	Banholzer, Rolf, et al	
		US-			

		FOREIGN F	ATENT DOCU	JMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T_{6}
		WO 97/47286	12/18/1997	Minnesota Mining & M		
						Щ

Examiner	Date	
Signature	Consider	tu i

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO Complete if Known Application Number 10/608,753 Filing Date INFORMATION DISCLOSURE 06/27/2003 STATEMENT BY APPLICANT First Named Inventor Karl-Heinz BOZUNG Art Unit 1614 (Use as many sheets as necessary) Examiner Name E. WEBMAN Sheet Attorney Docket Number 2 1/1088-3-C2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

		NON PATENT LITERATURE DOCUMENTS	
		T	_
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		SCHMELZER, CHRISTEL; et al; U.S. Application No. 10/054,567, Pharmaceutical Compositionis based on Tiotropium Salts and Salts of Salmeterol filed 11/13/2001, Attorney Docket NO. 1/1171	
		SCHMELZER, CHRISTEL; Office Action dated March 30, 2006 for U.S. Applicaton 10/054,567 Pharmaceutical Compositionis based on Tiotropium Salts and Salts of Salmeterol filed 11/13/2001, Attorney Docket NO. 1/1171	
			<u> </u>
			<u> </u>
		<u> </u>	
			†
			<u> </u>
			<u>L</u>
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.